- Home
- Publications
- Publication Search
- Publication Details
Title
Targets for Ibrutinib Beyond B Cell Malignancies
Authors
Keywords
-
Journal
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
Volume 82, Issue 3, Pages 208-217
Publisher
Wiley
Online
2015-06-25
DOI
10.1111/sji.12333
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma
- (2015) Shuang Q. Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma
- (2015) D. Masso-Valles et al. CANCER RESEARCH
- Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia
- (2015) Esther S. Kim et al. DRUGS
- Distinct Pathways Regulate Syk Protein Activation Downstream of Immune Tyrosine Activation Motif (ITAM) and hemITAM Receptors in Platelets
- (2015) Bhanu Kanth Manne et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury
- (2015) Minako Ito et al. Nature Communications
- Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma
- (2015) Laura Soucek et al. NEOPLASIA
- Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
- (2014) M. Levade et al. BLOOD
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
- (2014) J. R. McMullen et al. BLOOD
- Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
- (2014) H. E. Kohrt et al. BLOOD
- Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
- (2014) Gerard Milano et al. CURRENT DRUG TARGETS
- Ibrutinib: First Global Approval
- (2014) Fiona Cameron et al. DRUGS
- B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells
- (2014) Vaclav Seda et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
- (2014) Matthew S Davids et al. Future Oncology
- Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells
- (2014) Nicole Grabinski et al. INVESTIGATIONAL NEW DRUGS
- Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation
- (2014) Vassilios Lougaris et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells
- (2014) Julio Gomez-Rodriguez et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Selective Expression Rather than Specific Function of Txk and Itk Regulate Th1 and Th2 Responses
- (2014) N. Sahu et al. JOURNAL OF IMMUNOLOGY
- Dual Functions of Bruton's Tyrosine Kinase and Tec Kinase during Fc Receptor-Induced Signaling and Phagocytosis
- (2014) J. Jongstra-Bilen et al. JOURNAL OF IMMUNOLOGY
- Essential Roles for the Tec Family Kinases Tec and Btk in M-CSF Receptor Signaling Pathways That Regulate Macrophage Survival
- (2014) M. Melcher et al. JOURNAL OF IMMUNOLOGY
- The Tec Kinases Itk and Rlk Regulate NKT Cell Maturation, Cytokine Production, and Survival
- (2014) M. Felices et al. JOURNAL OF IMMUNOLOGY
- Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells
- (2014) Wen Gao et al. JNCI-Journal of the National Cancer Institute
- Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
- (2014) S Kamel et al. LEUKEMIA
- Reduced B Lymphoid Kinase (Blk) Expression Enhances Proinflammatory Cytokine Production and Induces Nephrosis in C57BL/6-lpr/lpr Mice
- (2014) Elizabeth M. Samuelson et al. PLoS One
- Erbb2 Is Required for Cardiac Atrial Electrical Activity during Development
- (2014) Gennadiy Tenin et al. PLoS One
- The Non-receptor Tyrosine Kinase Tec Controls Assembly and Activity of the Noncanonical Caspase-8 Inflammasome
- (2014) Florian Zwolanek et al. PLoS Pathogens
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss
- (2013) Masahiro Shinohara et al. BONE
- Agammaglobulinemia: causative mutations and their implications for novel therapies
- (2013) Anna Berglöf et al. Expert Review of Clinical Immunology
- Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life
- (2013) Paul R. Hess et al. JOURNAL OF CLINICAL INVESTIGATION
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
- (2013) Jan A. Burger et al. LEUKEMIA & LYMPHOMA
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases
- (2013) L. Vargas et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Deletion of the Endothelial Bmx Tyrosine Kinase Decreases Tumor Angiogenesis and Growth
- (2012) T. Holopainen et al. CANCER RESEARCH
- IL-2-Inducible T-Cell Kinase Deficiency with Pulmonary Manifestations due to Disseminated Epstein-Barr Virus Infection
- (2012) D. Mansouri et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- BMX and Its Role in Inflammation, Cardiovascular Disease, and Cancer
- (2012) Bruno Cenni et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Regulation of T-cell Responses and Disease by Tec Kinase Itk
- (2012) Avery August et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Tyrosine Kinase Btk Is Required for NK Cell Activation
- (2012) Yan Bao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases
- (2012) R M Linka et al. LEUKEMIA
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- Defects in acute responses to TLR4 in Btk-deficient mice result in impaired dendritic cell-induced IFN-γ production by natural killer cells
- (2011) Joan Ní Gabhann et al. CLINICAL IMMUNOLOGY
- Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates
- (2011) Julio Gomez-Rodriguez et al. FEBS Journal
- Absence of Tec Family Kinases Interleukin-2 Inducible T cell Kinase (Itk) and Bruton's Tyrosine Kinase (Btk) Severely Impairs FcϵRI-dependent Mast Cell Responses
- (2011) Archana S. Iyer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
- (2011) Betty Y Chang et al. ARTHRITIS RESEARCH & THERAPY
- Stress signaling by Tec tyrosine kinase in the ischemic myocardium
- (2010) Michael J. Zhang et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Targeted covalent drugs of the kinase family
- (2010) Juswinder Singh et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts
- (2010) Lynett Danks et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The Protein Tyrosine Kinase Tec Regulates a CD44highCD62L- Th17 Subset
- (2010) N. Boucheron et al. JOURNAL OF IMMUNOLOGY
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Immune System and Cancer
- (2009) David Loose et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- ITK Inhibitors in Inflammation and Immune-Mediated Disorders
- (2009) Nisebita Sahu et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- The protein tyrosine kinase Tec regulates mast cell function
- (2009) Uwe Schmidt et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The Tec kinases Itk and Rlk regulate conventional versus innate T-cell development
- (2009) Amanda L. Prince et al. IMMUNOLOGICAL REVIEWS
- Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals
- (2008) Masahiro Shinohara et al. CELL
- The Tec Family Tyrosine Kinase Btk Regulates RANKL-induced Osteoclast Maturation
- (2008) Seoung Hoon Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia
- (2007) Hiromichi Taneichi et al. CLINICAL IMMUNOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started